Related Experiment Video
Updated: Jul 13, 2026
07:13
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Update on pharmacoeconomics in transplantation
Teresa M Cavanaugh1, Jill E Martin
1University Hospital, University of Cincinnati College of Pharmacy, Cincinnati, OH, USA.
Progress in Transplantation (Aliso Viejo, Calif.)
|July 13, 2007
Summary
This review synthesizes pharmacoeconomic outcomes in transplantation over six years, highlighting drug therapy costs and their impact on clinical and humanistic results for better patient care.
Area of Science:
- Pharmacoeconomics
- Transplantation Medicine
- Health Economics
Background:
- Provides context for evaluating new pharmacoeconomic data in transplantation.
- Establishes the importance of economic evaluations in healthcare.
Purpose of the Study:
- To present current pharmacoeconomic outcomes in transplantation over the past six years.
- To analyze the cost of drug therapy in transplant patients.
Main Methods:
- Conducted an extensive literature search using PubMed and other internet sources.
- Included studies with updated pharmacoeconomic data on economic, clinical, and humanistic outcomes.
- Stratified data by pharmacoeconomic methods, therapies, and adverse event management.
Main Results:
- Extracted significant findings and limitations from selected studies.
- Analyzed costs associated with maintenance and induction therapies.
- Examined costs related to adverse events and quality-of-life issues.
Conclusions:
- Pharmacoeconomic analysis is crucial for determining optimal transplantation regimens.
- Continued evolution of these analyses is needed for cost-effective patient care.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...